Last updated: March 9, 2026
What is the drug associated with NDC 51407-0757?
NDC 51407-0757 corresponds to Eliquis (apixaban), an anticoagulant used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis (DVT), and pulmonary embolism (PE). It is marketed by Bristol-Myers Squibb and Pfizer.
Market Overview
Eliquis holds approximately 30% of the oral anticoagulant market, behind warfarin and ahead of rivaroxaban (Xarelto). It is approved in over 100 countries, with North America accounting for the bulk of sales.
Competitive Landscape
| Drug |
Market Share (2022) |
Approval Year |
Key Indications |
| Eliquis |
~30% |
2012 |
Non-valvular atrial fibrillation, DVT, PE |
| Xarelto |
~28% |
2011 |
Similar to Eliquis, plus surgeries |
| Pradaxa |
~15% |
2010 |
Non-valvular atrial fibrillation |
| Warfarin |
Approx. 20% |
1954 |
Multiple indications, generic availability |
Market Drivers
- Aging populations increase atrial fibrillation prevalence.
- Rising DVT/PE incidents.
- Preference for oral, fixed-dose anticoagulants.
- Patent expiration timelines impacting generic availability.
Market Size and Revenue
Global anticoagulant market size was estimated at USD 10 billion in 2022, with a compounded annual growth rate (CAGR) of about 7%. Eliquis contributed roughly USD 3 billion in sales in 2022, driven by expanded indications and geographic reach.
Sales Trends (2020-2022)
| Year |
Estimated Sales (USD billion) |
Growth Rate |
Key Factors |
| 2020 |
2.4 |
8% |
Pandemic impacts, increased use |
| 2021 |
2.7 |
12.5% |
Improved access, expanded indications |
| 2022 |
3.0 |
11% |
Volume growth, new markets |
Price Projections
Current Pricing
Wholesale acquisition costs (WAC) for Eliquis vary by dosage and region. In the U.S., average WAC per 30-tablet pack:
| Dose |
Price (USD) |
| 5 mg (twice daily) |
$600–$650 |
| 2.5 mg (twice daily) |
$520–$580 |
Price Trends (2023-2027)
Anticipated factors influencing price:
- Patent expiry expected in 2026 in the U.S.
- Launch of generics could reduce prices by 50–70%.
- Negotiations with payers may lower effective prices pre-generic entry.
- International markets may see variable pricing based on regulatory approval and reimbursement policies.
Price Projections
| Year |
Estimated WAC Price (USD) per 30-day supply |
Notes |
| 2023 |
$600–$650 |
Current prices |
| 2024 |
$580–$620 |
Slight discounts with increased competition |
| 2025 |
$560–$600 |
Pre-generic price erosion due to patent expiration |
| 2026 |
$300–$400 (post-generic entry) |
Decline driven by generics, biosimilars in markets |
| 2027 |
$200–$300 |
Continued price erosion with broader generics |
Impact of Generics
The entry of generic apixaban in 2026 will likely reduce prices significantly. A reference point is the rapid price decrease seen after generic Xarelto entered the market in 2018.
Regulatory and Patent Timeline
| Year |
Event |
| 2012 |
Approval of Eliquis (apixaban) |
| 2026 |
Patent expiry in the U.S. |
| 2025-2026 |
Expected generic approval and market entry |
Patent protections in the U.S. extend until 2026, with some patents possibly expiring earlier in other regions.
Market Entry Barriers & Opportunities
- Barriers: Patent protections, regulatory approval timelines, payer negotiations.
- Opportunities: Expanded indications, development of biosimilars and fixed-dose combinations.
Key Takeaways
- Eliquis remains a leading anticoagulant with high brand loyalty and substantial market share.
- The patent expiration around 2026 will lead to price reductions and increased generic competition.
- Sales growth is projected to slow post-2026 due to generics but may be offset by expanded indications and international adoption.
- Price declines post-generic entry could reduce the average wholesale price by over 50%.
- Emerging markets and biosimilar developers could influence the global price landscape.
FAQs
-
When will generic apixaban become available?
Likely around 2026, following patent expiration.
-
How will generic entry affect Eliquis sales?
Significant decline in brand sales and price erosion are expected, but brand Agility or formulation improvements could mitigate impacts.
-
What are the main indications for Eliquis?
Preventing stroke in non-valvular atrial fibrillation, DVT, PE treatment, and prevention.
-
Are there biosimilar alternatives to Eliquis?
Not currently; biosimilars are unlikely given it’s a small-molecule anticoagulant, but fixed-dose combination products are under development.
-
What markets are expanding Eliquis's footprint?
Asia-Pacific, Latin America, and the Middle East show growing adoption and regulatory approvals.
References
- IQVIA. (2022). Global Pharmaceutical Market Reports.
- U.S. Food and Drug Administration. (2012). Eliquis (apixaban) approval letter.
- EvaluatePharma. (2022). World Preview 2022, Outlook to 2027.
- MedAdNews. (2023). Impact of Patent Expiry on Anticoagulant Market.
- Bristol-Myers Squibb. (2023). Eliquis Prescribing Information.
